An open-Label, multicenter Study of the efficacy and safety of an AM/PM treatment regimen with clobetasol propionate spray 0.05% and calcitriol ointment 3 μg/g in the management of plaque psoriasis

Cutis

Volumn 88, Issue 1, 2011, Pages 46-51

  Menter, Alan ^a   Sofen, Howard ^b   Smith, Stacy ^c   Papp, Kim ^d   Kempers, Steven ^e   Hudson, Charles P ^f   Colón, Luz E ^g   Johnson, Lori A ^g   Gottschalk, Ronald ^g  

^a BAYLOR RESEARCH INSTITUTE   (United States)

^b Sofen is from Dermatology Research Associates   (United States)

^c Dermatology and Consulting   (United States)

^d PROBITY MEDICAL RESEARCH   (Canada)

^e Minnesota Clinical Study Center   (United States)

^f Hudson Dermatology   (United States)

^g Galderma Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CLOBETASOL; GLUCOCORTICOID; VITAMIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; FEMALE; HUMAN; INTRADERMAL DRUG ADMINISTRATION; MALE; MIDDLE AGED; MULTICENTER STUDY; OINTMENT; PATHOLOGY; PSORIASIS; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALCITRIOL; CLOBETASOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PSORIASIS; TREATMENT OUTCOME; VITAMINS; YOUNG ADULT;

EID: 80052929567     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Strowd LC, Yentzer BA, Fleischer AB Jr, et al. Increasing use of more potent treatments for psoriasis [published online ahead of print December 5, 2008]. J Am Acad Dermatol. 2009;60:478-481.
2. Schoepe S, Schäcke H, May E, et al. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15:406-420.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. section 3. guidelines of care for the management and treatment of psoriasis with topical therapies [published online ahead of print February 13, 2009]. J Am Acad Dermatol. 2009;60:643-659.
4. Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. J Am Acad Dermatol. 2005;53(1, suppl 1):S17-S25.
5. Austad J, Bjerke JR, Gjertsen BT, et al. Clobetasol pro-pionate followed by calcipotriol is superior to calcipo-triol alone in topical treatment of psoriasis. J Eur Acad Dermatol Venereol. 1998;11:19-24.
6. Lebwohl M, Yoles A, Lombardi K, et al. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement. J Am Acad Dermatol. 1998;39:447-450.
7. Toole JW. Calcipotriol and betamethasone dipropionate for the treatment of psoriasis: a 52-week study. Skin Therapy Lett. 2007;12:1-3.
8. Warino L, Balkrishnan R, Feldman SR. Clobetasol propionate for psoriasis: are ointments really more potent? JDrugs Dermatol. 2006;5:527-532.
9. Lebwohl M, Menter A, Weiss J, et al. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol. 2007;6:428-435.
10. Lebwohl M, Ortonne JP, Andres P, et al. Calcitriol oint-ment 3 microg/g is safe and effective over 52 weeks for the treatment of mild to moderate plaque psoriasis. Cutis.2009;83:205-212.